The FDA has approved Wegovy, the first daily oral weight-loss medication, giving Novo Nordisk an advantage over Eli Lilly. Both drugs are GLP-1 medications that help control appetite. Wegovy pills are expected to be available soon, potentially expanding access to obesity treatments. Clinical trials show significant weight loss with Wegovy compared to placebos. The cost of the new oral medication is expected to be lower than injections, with a starting price of $149 per month. Experts emphasize the importance of accessibility and affordability in weight-loss medications. Teljes cikk (Euronews.com)